Welcome to our dedicated page for Amgen news (Ticker: AMGN), a resource for investors and traders seeking the latest updates and insights on Amgen stock.
Amgen Inc. reports developments across its biotechnology medicines business, including discovery, development, manufacturing and delivery of human therapeutics. Company updates center on a portfolio and pipeline spanning cancer, inflammatory conditions, rare diseases, heart disease, obesity and obesity-related conditions, with named products and programs such as TEPEZZA, Repatha and IMDELLTRA appearing in clinical and commercial announcements.
Recurring news also covers quarterly financial results, non-GAAP performance measures, manufacturing network investments, supply-chain capacity, research collaborations, medical and investor conference presentations, and executive or organizational changes tied to the integration of biology, technology, artificial intelligence and data across Amgen's operations.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Amgen will release its first quarter financial results on April 27, 2023, post market closure. The announcement will be followed by a conference call at 1:30 p.m. PT, featuring CEO Robert A. Bradway and senior management. Participants can access a live audio broadcast of the call, which will be available for replay for at least 90 days. Amgen, a leading biotechnology firm with a rich pipeline of medicines, was recognized in 2022 by Forbes as one of the "World's Best Employers" and by Barron's as one of "America's 100 Most Sustainable Companies." The company is part of both the Dow Jones Industrial Average and the Nasdaq-100 index.